Cohort Studyhigh evidence
Generalizable AI predicts immunotherapy outcomes across cancers and treatments.
Nature medicine·July 3, 2026·PMID 42399673
Why it mattersCurrent immunotherapy biomarkers generalize poorly across tumor types and treatments. COMPASS offers a robust, interpretable tool that could improve patient selection and trial design by predicting response and highlighting actionable resistance mechanisms.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled